SEC EDGARJUN 22 min read$GILD

O'Day Daniel Patrick sold $138K of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 1,038 shares of GILEAD SCIENCES, INC. (GILD) at $132.97 ($0.14M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · O'Day Daniel Patrick

Published Jun 2, 2026, 10:04 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 2, 2026, 10:06 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$GILD

Neutral

medium confidence

Mentioned

$GILD

Relevance

6/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$GILDNeutralLow

Why it matters

The disclosure provides a datapoint on insider liquidity/compensation but does not introduce new company fundamentals or guidance.

Market read

A routine 10b5-1 insider sale; likely limited trading impact absent other catalysts.

What to watch

Traders may over-weight small insider sales; the key is whether there are multiple consecutive insider transactions or changes in plan behavior, which are not provided here.

Relevance 6/10Novelty 3/10Timing: Filed today; sale executed 2026-06-01

Background

SEC Form 4 discloses insider transactions; this one is an open-market sale by Gilead’s Chairman & CEO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GILDNeutralMedium confidence

Context

Gilead CEO/Chairman O'Day sold $138K of GILD shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 open-market sale, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying fundamental catalyst disclosed.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector/regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may be mechanically scheduled and not reflect bearish expectations—treat as noise unless paired with other negative signals.

Key entities

issuer
Gilead Sciences, Inc.
Subject of the insider sale disclosure (Form 4).
insider
O'Day Daniel Patrick
Chairman & CEO who sold 1,038 shares at ~$132.97 on 2026-06-01 under a 10b5-1 plan.

Read at source ← All news

SEP 5

$GILDHighAI 8/10

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Gilead Sciences (GILD) received three FDA approvals in four months, boosting its stock 21% YTD. Recent approvals include Bixlenvo for HIV and Trodelvy for breast cancer. The company expects more approvals, including anito-cel for multiple myeloma by year-end. Gilead's Q2 revenue was $7.6B, up 8% YoY, with strong HIV drug sales. The company raised its dividend to $0.82, yielding 2.15%.

yahoo.com3 min

SEP 3

$GILDHighAI 8/10

Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?

Gilead Sciences (GILD) shares rose 13.6% since its last earnings report. Q2 2026 saw a narrower adjusted loss of $6.75 per share and revenue growth of 10% to $7.80 billion, driven by HIV portfolio and Trodelvy. GILD raised full-year HIV sales growth guidance to 9-10%.

finance.yahoo.com3 min

SEP 2

$MRKLowAI 8/10

Once-Weekly Oral Combination HIV Pill Shows Promise As Alternative to Daily Treatment

Merck and Gilead Sciences are developing a weekly oral HIV treatment combining islatravir and lenacapavir, both FDA-approved separately. The combination aims to offer an alternative to daily HIV medication.

healthandme.com1 min

SEP 2

$GILDHighAI 9/10

Tablet Regimen for Virologically Suppressed Adults Living with HIV

The FDA approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV treatment for virologically suppressed adults. The drug combines bictegravir and lenacapavir, simplifying therapy and reducing pill burden. Clinical trials showed non-inferior viral suppression rates and improved health metrics. Bixlenvo is designed for patients with complex treatment histories or resistance challenges.

geneonline.com2 min

AUG 31

$GILDHighAI 9/10

A new once-daily pill to treat HIV just got the FDA’s green light

The FDA approved Gilead Sciences' once-daily HIV pill, Bixlenvo, for adults with suppressed HIV who cannot use current single-pill treatments. It combines bictegravir and lenacapavir, with a list price of $4,595 per month. Gilead aims to provide more treatment options, especially for older patients with complex regimens. According to the company, this group represents about 5% of HIV patients in the U.S.

advocate.com2 min